Description
In the current era, new products and research are being released at a rapid rate. In the hospital setting, what is the best way to assess if the new approach is safe and effective for infants and children? In this session, three experts in pediatric hematology, pediatric critical care and pediatric transfusion will share the newest developments in the field. The speakers will lead the audience through the decision making assessments of how to consider new evidence and impact practice changes as well as how to assess clinical situations when there is not a lot of published evidence in the pediatric population. The speakers will also consider how not implementing new practices or products may impact care.
Learning Objectives:
- Explain the different prophylactic thresholds for neonatal platelet transfusion and how new research has updated our knowledge.
- Assess the reasons for using fresh blood in pediatric critical care patients and determine the evidence based approach to blood bank inventory management.
- Differentiate a group of new transfusion and pharmaceutical products to determine their use in pediatric patients.
Speaker(s):
- Jennifer
Andrews,
MD,
Associate Professor of Pathology, Microbiology and Immunology, Associate Professor of Pediatrics, Medical Director, Blood Bank,
Vanderbilt University Medical Center
- Dr. Allan
Doctor,
MD,
University of Maryland School of Medicine
- Simon
Stanworth,
MA, FRCP (Paeds, UK), PhD, FRCPath,
Consultant Hematologist,
NHS Blood and Transplant
Disclosures
- Jennifer Andrews, MD : Cerus Corporation: Honoraria
- Allan Doctor, MD : Stockholder: KaloCyte Inc.; Grant/research Support: KaolCyte Inc.
- Simon Stanworth, MA, FRCP (Paeds, UK), PhD, FRCPath : Nothing to disclose
